MAQS advised Ribocure on global licensing agreement with Madrigal

Suzhou Ribo Life Science Co. Ltd (Ribo) and its subsidiary Ribocure Pharmaceuticals AB (Ribocure) have entered into an exclusive worldwide licensing agreement with Madrigal Pharmaceuticals, Inc. (Madrigal) for six pre-clinical small interfering RNA (siRNA) programs for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). 

The collaboration will utilize Ribo’s validated liver targeting siRNA GalSTAR ™ platform to develop novel treatments for MASH. 

Under the agreement, Ribo has granted Madrigal an exclusive global license to develop, manufacture, and commercialize several siRNA assets. Ribo will receive an upfront payment of US$60M, and cumulative payments could reach US$4.4B if certain development, regulatory and commercial milestones are achieved, as well as potential royalties on net sales.

MAQS Advokatbyrå acted as legal advisor to Ribocure in connection with the global licensing agreement. Niklas Eskilsson led the team.